{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:24:17Z","timestamp":1790400257759,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Therapeutics LP","award":["PCT\/EP2011\/069147"],"award-info":[{"award-number":["PCT\/EP2011\/069147"]}]},{"name":"Therapeutics LP","award":["PCT\/US2017\/049691"],"award-info":[{"award-number":["PCT\/US2017\/049691"]}]},{"name":"Therapeutics LP","award":["PCT\/US2017\/026382"],"award-info":[{"award-number":["PCT\/US2017\/026382"]}]},{"name":"Therapeutics LP","award":["16759325.0 EP2017"],"award-info":[{"award-number":["16759325.0 EP2017"]}]},{"name":"Therapeutics LP","award":["16759326.8 EP2017"],"award-info":[{"award-number":["16759326.8 EP2017"]}]},{"name":"Health Innovation Challenge Fund","award":["HICF-R8-433"],"award-info":[{"award-number":["HICF-R8-433"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"180 Therapeutics"},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Oxford Biomedical Research Centre"}],"content-domain":{"domain":["ebiomedicine.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ebiom.2018.06.022","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T10:58:02Z","timestamp":1530874682000},"page":"282-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9579-9411","authenticated-orcid":false,"given":"Jagdeep","family":"Nanchahal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona E.","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Cabrita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Swettenham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Cahoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethan","family":"Copsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Anne Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki S.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2018.06.022_bb0005","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s11552-008-9160-9","article-title":"Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology","volume":"4","author":"Hindocha","year":"2009","journal-title":"Hand (N Y)"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0010","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jhsa.2005.03.005","article-title":"A retrospective review of the management of Dupuytren's nodules","volume":"30","author":"Reilly","year":"2005","journal-title":"J Hand Surg"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jht.2014.11.006","article-title":"Factors affecting functional recovery after surgery and hand therapy in patients with Dupuytren's disease","volume":"28","author":"Engstrand","year":"2015","journal-title":"J Hand Ther"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/1753193412467170","article-title":"Surgical treatment of primary Dupuytren's contractures of the fingers in the UK: surgeons' preferences and research priorities","volume":"38","author":"Davis","year":"2013","journal-title":"J Hand Surg Eur Vol"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0025","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jhsa.2016.07.090","article-title":"The impact of collagenase Clostridium histolyticum introduction on Dupuytren treatment patterns in the United States","volume":"41","author":"Zhao","year":"2016","journal-title":"J Hand Surg"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0030","first-page":"101","article-title":"Dupuytren's disease: anatomy, pathology, presentation, and treatment","volume":"56","author":"Rayan","year":"2007","journal-title":"Instr Course Lect"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0035","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/PRS.0b013e31823aea95","article-title":"Five-year results of a randomized clinical trial on treatment in Dupuytren's disease: percutaneous needle fasciotomy versus limited fasciectomy","volume":"129","author":"van Rijssen","year":"2012","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0040","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/1753193410397971","article-title":"The efficacy and safety of fasciectomy and fasciotomy for Dupuytren's contracture in European patients: a structured review of published studies","volume":"36","author":"Crean","year":"2011","journal-title":"J Hand Surg Eur Vol"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1753193414528843","article-title":"Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren's contracture","volume":"40","author":"Peimer","year":"2015","journal-title":"J Hand Surg Eur Vol"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0050","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1056\/NEJMoa0810866","article-title":"Injectable collagenase clostridium histolyticum for Dupuytren's contracture","volume":"361","author":"Hurst","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0055","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12891-016-1200-y","article-title":"Systematic review of non-surgical treatments for early dupuytren's disease","volume":"17","author":"Ball","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0060","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12891-017-1713-z","article-title":"Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomized controlled trial","volume":"18","author":"Costas","year":"2017","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0065","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00018-015-2110-0","article-title":"The myofibroblast, a key cell in normal and pathological tissue repair","volume":"73","author":"Darby","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0070","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0075","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2353\/ajpath.2007.070112","article-title":"The myofibroblast: one function, multiple origins","volume":"170","author":"Hinz","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0080","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.1073\/pnas.1607896113","article-title":"Strategies to overcome the hurdles to treat fibrosis, a major unmet clinical need","volume":"113","author":"Nanchahal","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0085","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jhsa.2009.08.005","article-title":"Myofibroblast distribution in Dupuytren's cords: correlation with digital contracture","volume":"34","author":"Verjee","year":"2009","journal-title":"J Hand Surg"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0090","doi-asserted-by":"crossref","first-page":"E928","DOI":"10.1073\/pnas.1301100110","article-title":"Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target","volume":"110","author":"Verjee","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1101029","article-title":"Wnt signaling and Dupuytren's disease","volume":"365","author":"Dolmans","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0100","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ajhg.2017.08.006","article-title":"A genome-wide association study of dupuytren disease reveals 17 additional variants implicated in fibrosis","volume":"101","author":"Ng","year":"2017","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0105","author":"Nanchahal","year":"2017","journal-title":"Wellcome Open Res."},{"key":"10.1016\/j.ebiom.2018.06.022_bb0110","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0115","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1242\/jcs.01731","article-title":"Procollagen trafficking, processing and fibrillogenesis","volume":"118","author":"Canty","year":"2005","journal-title":"J Cell Sci"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0120","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/1753193410362848","article-title":"Re-visiting Luck's classification: a histological analysis of Dupuytren's disease","volume":"35","author":"Lam","year":"2010","journal-title":"J Hand Surg Eur Vol"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0125","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jcp.22167","article-title":"Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells","volume":"224","author":"Verjee","year":"2010","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0130","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/wrna.1177","article-title":"RNA protein interactions governing expression of the most abundant protein in human body, type I collagen","volume":"4","author":"Stefanovic","year":"2013","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0135","author":"Abbvie"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0140","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1136\/annrheumdis-2013-203893","article-title":"Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis","volume":"74","author":"Chen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0145","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1742-7843.2006.pto_271.x","article-title":"Pain perception after subcutaneous injections of media containing different buffers","volume":"98","author":"Laursen","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.ebiom.2018.06.022_bb0150","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396418302299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396418302299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T17:44:34Z","timestamp":1565286274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396418302299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":30,"alternative-id":["S2352396418302299"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2018.06.022","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733611105.793549751","asserted-by":"object"}]},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2018.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}